Concepts (215)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| HIV-1 | 12 | 2021 | 3365 | 1.68 | Why? |
| HIV Infections | 19 | 2021 | 11620 | 1.64 | Why? |
| Sex Workers | 3 | 2019 | 348 | 1.53 | Why? |
| Central African Republic | 8 | 2020 | 37 | 1.38 | Why? |
| AIDS Serodiagnosis | 2 | 2018 | 64 | 1.33 | Why? |
| Self Care | 3 | 2019 | 918 | 1.22 | Why? |
| Syphilis | 2 | 2019 | 318 | 1.08 | Why? |
| Hepatitis B | 3 | 2018 | 888 | 0.89 | Why? |
| Drug Resistance, Viral | 2 | 2019 | 1083 | 0.89 | Why? |
| Diagnostic Tests, Routine | 3 | 2018 | 2643 | 0.87 | Why? |
| Papillomavirus Infections | 3 | 2019 | 861 | 0.85 | Why? |
| Syphilis Serodiagnosis | 1 | 2019 | 30 | 0.79 | Why? |
| Papillomaviridae | 3 | 2019 | 404 | 0.79 | Why? |
| Treponema pallidum | 1 | 2019 | 42 | 0.77 | Why? |
| Hepatitis B Surface Antigens | 2 | 2018 | 305 | 0.76 | Why? |
| Homosexuality, Male | 2 | 2018 | 1158 | 0.75 | Why? |
| Anus Diseases | 1 | 2018 | 55 | 0.71 | Why? |
| HIV-2 | 1 | 2017 | 92 | 0.68 | Why? |
| Hepatitis C Antibodies | 1 | 2017 | 120 | 0.67 | Why? |
| Sex Work | 1 | 2017 | 96 | 0.67 | Why? |
| Unsafe Sex | 1 | 2017 | 139 | 0.65 | Why? |
| Nucleic Acid Amplification Techniques | 2 | 2021 | 3388 | 0.63 | Why? |
| Herpes Genitalis | 2 | 2014 | 90 | 0.63 | Why? |
| Antigens, Bacterial | 1 | 2019 | 330 | 0.62 | Why? |
| Chromatography, Affinity | 1 | 2017 | 310 | 0.60 | Why? |
| HIV Protease Inhibitors | 1 | 2019 | 434 | 0.59 | Why? |
| Educational Status | 2 | 2019 | 1451 | 0.58 | Why? |
| Fingers | 1 | 2018 | 221 | 0.58 | Why? |
| Immunoglobulin M | 3 | 2021 | 9091 | 0.56 | Why? |
| False Positive Reactions | 4 | 2021 | 1338 | 0.54 | Why? |
| Point-of-Care Testing | 3 | 2021 | 2782 | 0.51 | Why? |
| Reagent Kits, Diagnostic | 2 | 2020 | 2149 | 0.50 | Why? |
| Democratic Republic of the Congo | 3 | 2019 | 500 | 0.49 | Why? |
| CD4 Lymphocyte Count | 1 | 2018 | 1517 | 0.48 | Why? |
| Hot Temperature | 1 | 2020 | 1299 | 0.48 | Why? |
| Papillomavirus Vaccines | 1 | 2017 | 405 | 0.45 | Why? |
| HIV Antibodies | 1 | 2017 | 776 | 0.44 | Why? |
| Mass Screening | 7 | 2020 | 8005 | 0.43 | Why? |
| Virus Inactivation | 1 | 2020 | 1139 | 0.43 | Why? |
| Genes, pol | 2 | 2017 | 38 | 0.41 | Why? |
| Hepatitis C | 2 | 2018 | 1514 | 0.40 | Why? |
| Leadership | 2 | 2020 | 2241 | 0.39 | Why? |
| Immunoglobulin G | 5 | 2021 | 21571 | 0.38 | Why? |
| Receptors, CCR5 | 2 | 2010 | 186 | 0.37 | Why? |
| Nucleocapsid Proteins | 1 | 2021 | 3120 | 0.37 | Why? |
| Uterine Cervical Neoplasms | 1 | 2017 | 842 | 0.36 | Why? |
| Interleukin-13 | 1 | 2010 | 204 | 0.36 | Why? |
| Anti-Retroviral Agents | 1 | 2017 | 1099 | 0.36 | Why? |
| Interleukin-4 | 1 | 2010 | 367 | 0.36 | Why? |
| Hepacivirus | 1 | 2017 | 1509 | 0.35 | Why? |
| Sensitivity and Specificity | 8 | 2021 | 22971 | 0.34 | Why? |
| Genotype | 5 | 2019 | 4697 | 0.32 | Why? |
| Health Services Needs and Demand | 1 | 2020 | 3419 | 0.30 | Why? |
| Early Detection of Cancer | 1 | 2017 | 1956 | 0.29 | Why? |
| France | 5 | 2021 | 12074 | 0.28 | Why? |
| Nasopharynx | 2 | 2021 | 10224 | 0.28 | Why? |
| Sexual Behavior | 3 | 2018 | 1322 | 0.27 | Why? |
| Patient Acceptance of Health Care | 2 | 2019 | 5002 | 0.27 | Why? |
| Antigens, Viral | 1 | 2021 | 6298 | 0.26 | Why? |
| Condoms, Female | 1 | 2002 | 2 | 0.26 | Why? |
| Anti-HIV Agents | 3 | 2012 | 2209 | 0.26 | Why? |
| Africa | 3 | 2020 | 2986 | 0.25 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2018 | 4545 | 0.24 | Why? |
| Adolescent | 13 | 2020 | 86841 | 0.24 | Why? |
| Clinical Laboratory Techniques | 3 | 2020 | 23402 | 0.24 | Why? |
| Drug Resistance, Multiple, Viral | 1 | 2002 | 37 | 0.24 | Why? |
| HIV | 3 | 2018 | 1116 | 0.24 | Why? |
| Sexually Transmitted Diseases | 3 | 2018 | 694 | 0.23 | Why? |
| Treatment Failure | 2 | 2019 | 2106 | 0.23 | Why? |
| Reproducibility of Results | 4 | 2021 | 11304 | 0.23 | Why? |
| Chad | 1 | 2020 | 25 | 0.23 | Why? |
| RNA-Directed DNA Polymerase | 1 | 2002 | 170 | 0.22 | Why? |
| Reverse Transcriptase Inhibitors | 2 | 2019 | 309 | 0.22 | Why? |
| RNA, Viral | 6 | 2021 | 32276 | 0.22 | Why? |
| Students | 1 | 2019 | 5255 | 0.21 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2021 | 13720 | 0.21 | Why? |
| Viral Load | 6 | 2021 | 15850 | 0.21 | Why? |
| Humans | 44 | 2021 | 930598 | 0.21 | Why? |
| Self Administration | 1 | 2020 | 125 | 0.21 | Why? |
| Africa South of the Sahara | 4 | 2020 | 1335 | 0.21 | Why? |
| Algorithms | 1 | 2017 | 7346 | 0.20 | Why? |
| DNA, Viral | 2 | 2018 | 2521 | 0.19 | Why? |
| Lymphoma, B-Cell | 1 | 2021 | 166 | 0.19 | Why? |
| Retreatment | 1 | 2019 | 186 | 0.19 | Why? |
| Prospective Studies | 7 | 2021 | 43301 | 0.19 | Why? |
| Cross-Sectional Studies | 7 | 2019 | 53120 | 0.18 | Why? |
| Sexual Harassment | 1 | 2019 | 62 | 0.18 | Why? |
| Africa, Central | 1 | 2017 | 29 | 0.18 | Why? |
| Young Adult | 11 | 2020 | 93724 | 0.18 | Why? |
| Coitus | 1 | 2017 | 44 | 0.17 | Why? |
| Cameroon | 1 | 2019 | 464 | 0.17 | Why? |
| Macrophages | 1 | 2010 | 2784 | 0.17 | Why? |
| Antibodies, Viral | 5 | 2021 | 51949 | 0.17 | Why? |
| Oropharyngeal Neoplasms | 1 | 2019 | 138 | 0.17 | Why? |
| Adult | 16 | 2021 | 244371 | 0.17 | Why? |
| Monitoring, Immunologic | 1 | 2018 | 153 | 0.17 | Why? |
| Serologic Tests | 3 | 2020 | 4359 | 0.16 | Why? |
| Condoms | 1 | 2017 | 235 | 0.16 | Why? |
| Female | 17 | 2021 | 380317 | 0.16 | Why? |
| Male | 17 | 2021 | 367725 | 0.15 | Why? |
| Health Risk Behaviors | 1 | 2017 | 172 | 0.15 | Why? |
| Incidental Findings | 1 | 2020 | 487 | 0.15 | Why? |
| Equipment and Supplies | 1 | 2020 | 440 | 0.15 | Why? |
| Observer Variation | 1 | 2018 | 622 | 0.15 | Why? |
| Automation, Laboratory | 1 | 2018 | 536 | 0.14 | Why? |
| Pneumonia, Viral | 7 | 2020 | 243684 | 0.14 | Why? |
| Coronavirus Infections | 7 | 2020 | 253789 | 0.13 | Why? |
| Delivery of Health Care | 1 | 2020 | 15909 | 0.13 | Why? |
| Anemia, Sickle Cell | 1 | 2020 | 546 | 0.13 | Why? |
| Risk-Taking | 1 | 2018 | 508 | 0.13 | Why? |
| Antiretroviral Therapy, Highly Active | 1 | 2019 | 952 | 0.13 | Why? |
| Herpesvirus 2, Human | 1 | 2014 | 137 | 0.13 | Why? |
| Alleles | 1 | 2019 | 1557 | 0.13 | Why? |
| T-Lymphocytes | 2 | 2010 | 6670 | 0.12 | Why? |
| Interdisciplinary Communication | 1 | 2020 | 1425 | 0.12 | Why? |
| Acquired Immunodeficiency Syndrome | 1 | 2019 | 533 | 0.12 | Why? |
| Counseling | 1 | 2018 | 747 | 0.11 | Why? |
| Molecular Epidemiology | 1 | 2017 | 1638 | 0.11 | Why? |
| Fluorescent Antibody Technique | 1 | 2014 | 835 | 0.11 | Why? |
| Public Health | 1 | 2017 | 16359 | 0.11 | Why? |
| Herpesvirus 1, Human | 1 | 2014 | 286 | 0.11 | Why? |
| Acyclovir | 1 | 2011 | 154 | 0.11 | Why? |
| Immune Evasion | 1 | 2021 | 2081 | 0.11 | Why? |
| Virus Cultivation | 1 | 2014 | 579 | 0.10 | Why? |
| Phosphoproteins | 1 | 2021 | 4346 | 0.10 | Why? |
| Convalescence | 1 | 2021 | 2829 | 0.10 | Why? |
| Flow Cytometry | 1 | 2018 | 2393 | 0.09 | Why? |
| Surveys and Questionnaires | 4 | 2021 | 43792 | 0.09 | Why? |
| Plant Lectins | 1 | 2009 | 114 | 0.09 | Why? |
| HIV Envelope Protein gp41 | 1 | 2009 | 153 | 0.09 | Why? |
| Sexual and Gender Minorities | 1 | 2018 | 1019 | 0.09 | Why? |
| Mutation | 2 | 2019 | 12376 | 0.09 | Why? |
| Laboratories | 1 | 2020 | 2858 | 0.08 | Why? |
| Medication Adherence | 1 | 2017 | 1270 | 0.08 | Why? |
| Head and Neck Neoplasms | 1 | 2019 | 1568 | 0.08 | Why? |
| Amphibian Proteins | 1 | 2005 | 8 | 0.08 | Why? |
| Prevalence | 2 | 2018 | 25773 | 0.08 | Why? |
| Alcohol Drinking | 1 | 2017 | 1663 | 0.08 | Why? |
| Poverty | 1 | 2017 | 2302 | 0.07 | Why? |
| Predictive Value of Tests | 1 | 2021 | 9537 | 0.07 | Why? |
| Incidence | 2 | 2018 | 25622 | 0.07 | Why? |
| Middle Aged | 7 | 2021 | 270681 | 0.07 | Why? |
| Pandemics | 8 | 2020 | 389249 | 0.07 | Why? |
| Immunoassay | 1 | 2021 | 4485 | 0.07 | Why? |
| Seroepidemiologic Studies | 1 | 2020 | 10017 | 0.07 | Why? |
| Child | 3 | 2019 | 70012 | 0.07 | Why? |
| Politics | 1 | 2018 | 1824 | 0.07 | Why? |
| World Health Organization | 1 | 2017 | 4213 | 0.07 | Why? |
| Molecular Diagnostic Techniques | 1 | 2020 | 4239 | 0.07 | Why? |
| Child, Preschool | 2 | 2019 | 36283 | 0.07 | Why? |
| Universities | 1 | 2019 | 4374 | 0.07 | Why? |
| Logistic Models | 1 | 2019 | 9089 | 0.07 | Why? |
| Europe | 1 | 2020 | 12702 | 0.07 | Why? |
| Antimicrobial Cationic Peptides | 1 | 2005 | 159 | 0.06 | Why? |
| Cells, Cultured | 3 | 2010 | 5835 | 0.06 | Why? |
| Cell Differentiation | 1 | 2010 | 1338 | 0.06 | Why? |
| Substance-Related Disorders | 1 | 2017 | 2038 | 0.06 | Why? |
| Betacoronavirus | 5 | 2020 | 204454 | 0.06 | Why? |
| DNA Transposable Elements | 1 | 2002 | 91 | 0.06 | Why? |
| Proviruses | 1 | 2002 | 82 | 0.06 | Why? |
| Socioeconomic Factors | 1 | 2019 | 8495 | 0.05 | Why? |
| Phylogeny | 1 | 2019 | 13341 | 0.05 | Why? |
| Follow-Up Studies | 1 | 2018 | 17020 | 0.05 | Why? |
| Contraception | 1 | 2002 | 291 | 0.05 | Why? |
| Polymerase Chain Reaction | 1 | 2014 | 6740 | 0.05 | Why? |
| Family Planning Services | 1 | 2002 | 236 | 0.05 | Why? |
| Peptide Fragments | 1 | 2009 | 2075 | 0.05 | Why? |
| Human papillomavirus 16 | 1 | 2019 | 95 | 0.05 | Why? |
| Age Factors | 1 | 2019 | 21039 | 0.04 | Why? |
| Bullying | 1 | 2019 | 98 | 0.04 | Why? |
| Sexual Partners | 1 | 2002 | 612 | 0.04 | Why? |
| Time Factors | 1 | 2021 | 31397 | 0.04 | Why? |
| Coinfection | 1 | 2017 | 6820 | 0.04 | Why? |
| Paris | 1 | 2020 | 1287 | 0.04 | Why? |
| United Nations | 1 | 2019 | 367 | 0.04 | Why? |
| Molecular Sequence Data | 1 | 2002 | 3198 | 0.04 | Why? |
| Demography | 1 | 2002 | 1660 | 0.04 | Why? |
| Global Health | 1 | 2019 | 13911 | 0.04 | Why? |
| Health Knowledge, Attitudes, Practice | 1 | 2017 | 8811 | 0.03 | Why? |
| Aged | 3 | 2020 | 215776 | 0.03 | Why? |
| Antibodies, Neutralizing | 1 | 2021 | 25288 | 0.03 | Why? |
| Aged, 80 and over | 2 | 2020 | 88759 | 0.03 | Why? |
| Treatment Outcome | 1 | 2019 | 51732 | 0.03 | Why? |
| Vaccination | 1 | 2017 | 19050 | 0.03 | Why? |
| Blood Transfusion | 1 | 2020 | 1399 | 0.03 | Why? |
| Multiplex Polymerase Chain Reaction | 1 | 2019 | 1439 | 0.03 | Why? |
| Liliaceae | 1 | 2009 | 11 | 0.03 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 37182 | 0.03 | Why? |
| Ulcer | 1 | 2011 | 128 | 0.03 | Why? |
| Amino Acid Sequence | 1 | 2002 | 6049 | 0.03 | Why? |
| Biopsy | 1 | 2019 | 2811 | 0.03 | Why? |
| Antibodies, Monoclonal, Humanized | 2 | 2021 | 9335 | 0.02 | Why? |
| HIV Seropositivity | 1 | 2011 | 320 | 0.02 | Why? |
| Epitopes | 1 | 2021 | 4113 | 0.02 | Why? |
| Risk Factors | 1 | 2018 | 71621 | 0.02 | Why? |
| Microbial Sensitivity Tests | 2 | 2009 | 2886 | 0.02 | Why? |
| Lymphocytes | 1 | 2021 | 3056 | 0.02 | Why? |
| Neutralization Tests | 1 | 2021 | 6698 | 0.02 | Why? |
| Bacterial Infections | 1 | 2020 | 2229 | 0.02 | Why? |
| Drug Synergism | 1 | 2009 | 833 | 0.02 | Why? |
| Germany | 1 | 2020 | 9196 | 0.02 | Why? |
| Cell Survival | 1 | 2009 | 1581 | 0.02 | Why? |
| India | 1 | 2021 | 11875 | 0.02 | Why? |
| Cell Line | 2 | 2009 | 12040 | 0.01 | Why? |
| Dose-Response Relationship, Drug | 1 | 2009 | 3776 | 0.01 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2019 | 11367 | 0.01 | Why? |
| Critical Illness | 1 | 2021 | 17281 | 0.01 | Why? |
| Prognosis | 1 | 2020 | 32490 | 0.01 | Why? |
| Virion | 1 | 2005 | 1444 | 0.01 | Why? |
| Dendritic Cells | 1 | 2005 | 1330 | 0.01 | Why? |
| Severity of Illness Index | 1 | 2021 | 48226 | 0.01 | Why? |
| Epithelial Cells | 1 | 2005 | 3508 | 0.01 | Why? |
| Monocytes | 1 | 2005 | 2978 | 0.01 | Why? |
| Health Personnel | 1 | 2020 | 29646 | 0.01 | Why? |
| Animals | 1 | 2005 | 78931 | 0.00 | Why? |